Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

ZEMDRI

PLAZOMICIN SULFATE

Standard Dose
EQ 500MG BASE/10ML (EQ 50MG BASE/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ZEMDRI is listed in Drugs@FDA under application 210303 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PLAZOMICIN SULFATE Form and strength SOLUTION;INTRAVENOUS - EQ 500MG BASE/10ML (EQ 50MG BASE/ML) Sponsor CIPLA USA Submission history Latest submission status date: 2023-02-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZEMDRI is listed in Drugs@FDA under application 210303 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient PLAZOMICIN SULFATE Form and strength SOLUTION;INTRAVENOUS - EQ 500MG BASE/10ML (EQ 50MG BASE/ML) Sponsor CIPLA USA Submission history Latest submission status date: 2023-02-10 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.